Differential effects of haloperidol, clozapine and olanzapine on learning and memory functions in mice

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 30, Issue 8, 2006, Pages 1486-1495

  Hou, Yue ^a,b   Wu, Chun Fu ^a   Yang, Jing Yu ^a   Guo, Tao ^b  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

Author keywords

Clozapine; Haloperidol; Memory; Morris water maze; Olanzapine; Step through test

Indexed keywords

CLOZAPINE; HALOPERIDOL; OLANZAPINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEPTH PERCEPTION; DRUG EFFECT; DRUG SAFETY; EXPERIMENTAL MODEL; LEARNING; MALE; MAZE TEST; MEMORY; MEMORY CONSOLIDATION; MOUSE; NEUROTOXICITY; NONHUMAN; PASSIVE AVOIDANCE; TASK PERFORMANCE;

ANIMALS; ANTIPSYCHOTIC AGENTS; AVOIDANCE LEARNING; BENZODIAZEPINES; CLOZAPINE; HALOPERIDOL; LEARNING; MAZE LEARNING; MEMORY; MICE; MODELS, ANIMAL; MOTOR ACTIVITY; SWIMMING;

EID: 33750377539     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2006.06.001     Document Type: Article

References (58)

1. Antonova E., Sharma T., Morris R., and Kumari V. The relationship between brain structure and neurocognition in schizophrenia: a selective review. Schizophr Res 70 (2004) 117-145
2. Arnsten A.F.T. Catecholamine regulation of the prefrontal cortex. J Psychopharmacol 11 (1997) 151-162
3. Arnt J., and Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 18 (1998) 63-101
4. Bartus R.T. On neurodegenerative disease, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol 163 (2000) 495-529
5. Bilder R.M., Goldman R.S., Volavka J., Czobor P., Hoptman M., Sheitman B., et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 159 (2002) 1018-1028
6. Bymaster F., Perry K.W., Nelson D.L., Wong D.T., Rasmussen K., Moore N.A., et al. Olanzapine: a basic science update. Br J Psychiatry Suppl 37 (1999) 36-40
7. Bymaster F.P., Calligaro D.O., Falcone J.F., Marsh R.D., Moore N.A., Tye N.C., et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14 (1996) 87-96
8. Bymaster F.P., Falcone J.F., Bauzon D., Kennedy J.S., Schenck K., DeLapp N.W., et al. Potent antagonism of 5-HT(3) and 5-HT(6) receptors by olanzapine. Eur J Pharmacol 430 (2001) 341-349
9. Cassens G., Inglis A.K., Appelbaum P.S., and Gutheil T.G. Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients. Schizophr Bull 16 (1990) 477-499
10. Castellano C., Cestari V., Cabib S., and Puglisi-Allegra S. Post-training dopamine receptor agonists and antagonists affect memory storage in mice irrespective of their selectivity for D1 or D2 receptors. Behav Neural Biol 56 (1991) 283-291
11. Chen D., Wu C.F., Shi B., and Xu Y.M. Tamoxifen and toremifene cause impairment of learning and memory function in mice. Pharmacol Biochem Behav 71 (2002) 269-276
12. Chen D., Wu C.F., Shi B., and Xu Y.M. Tamoxifen and toremifene impair retrieval, but not acquisition, of spatial information processing in mice. Pharmacol Biochem Behav 72 (2002) 417-421
13. Cuesta M.J., Peralta V., and Zarzuela A. Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study. Schizophr Res 48 (2001) 17-28
14. Dawson L.A., Huy O., Nguyen B.S., and Li P. The 5-HT6 receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus. Neuropsychopharmacology 25 (2001) 662-668
15. DeLisi L.E., Stritzke P.H., Holan V., Anand A., Boccio A., Kuschner M., et al. Brain morphological changes in 1st episode cases of schizophrenia: are they progressive?. Schizophr Res 5 (1991) 206-208
16. Gooding D.C., Kwapil T.R., and Tallent K.A. Wisconsin Card Sorting Test deficits in schizotypic individuals. Schizophr Res 40 (1999) 201-209
17. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am J Psychiatry 153 (1996) 321-330
18. Green M.F., Marshall Jr. B.D., Wirshing W.C., Ames D., Marder S.R., McGurk S., et al. Does risperidone improve verbal working memory in treatment-resistant schizophrenia?. Am J Psychiatry 154 (1997) 799-804
19. Gur R.E., Turetsky B.I., Bilker W.B., and Gur R.C. Reduced gray matter volume in schizophrenia. Arch Gen Psychiatry 56 (1999) 905-911
20. Harvey P.D., Green M.F., McGurk S.R., and Meltzer H.Y. Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study. Psychopharmacology 169 (2003) 404-411
21. He H., and Richardson J.S. A pharmacological, pharmacokinetic and clinical overview of risperidone, a new antipsychotic that blocks serotonin 5-HT2 and dopamine D2 receptors. Int Clin Psychopharmacol 10 (1995) 19-30
22. Heaton R.K., Gladsjo J.A., Palmer B.W., Kuck J., Marcotte T.D., and Jeste D.V. Stability and course of neuropsychological deficits in schizophrenia. Arch Gen Psychiatry 58 (2001) 24-32
23. Ichihara K., Nabeshima T., and Kameyama T. Effects of haloperidol, sulpiride and SCH 23390 on passive avoidance learning in mice. Eur J Pharmacol 151 (1988) 435-442
24. Ichikawa J., Dai J., O'Laughlin I.A., Fowler W.L., and Meltzer H.Y. Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology 26 (2002) 325-339
25. Keefe R.S.E., Silva S.G., Perkins D.O., and Lieberman J.A. The effect of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull 25 (1999) 201-222
26. Keefe R.S., Young C.A., Rock S.L., Purdon S.E., Gold J.M., Breier A., et al. One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. Schizophr Res 81 (2006) 1-15
27. Kern R.S., Green M.F., Marshall Jr. B.D., Wirshing W.C., Wirshing D., McGurk S.R., et al. Risperidone versus haloperidol on secondary memory: can newer medications aid learning?. Schizophr Bull 25 (1999) 223-232
28. Levin E.D., and Johansson P.E. Cognitive effects of long-term chronic neuroleptic drug administration. Toxicologist 8 (1988) 77
29. Levin E.D., Wilson W., Rose J.E., and McEvory J. Nicotine-haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology 15 (1996) 429-436
30. Li B.M., and Mei Z.T. Delayed-response deficit induced by local injection of the α2-adrenergic antagonist yohimbine into the dorsolateral prefrontal cortex in young-adult monkeys. Behav Neural Biol 62 (1994) 134-139
31. Li X.M., Perry K.W., Wong D.T., and Bymaster F.P. Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum. Psychopharmacology 136 (1998) 153-161
32. Li B.M., Mao Z.M., Wang M., and Mei Z.T. α2-Adrenergic modulation of prefrontal cortical neuronal activity related to spatial working memory in monkeys. Neuropsychopharmacology 21 (1999) 601-610
33. Maher B.A., Manschreck T.C., Woods B.T., Yurgelun-Todd D.A., and Tsuang M.T. Frontal brain volume and context effects in short-term recall in schizophrenia. Biol Psychiatry 37 (1995) 144-150
34. McGurk S.R., Carter C., Goldman R., Green M.F., Marder S.R., Xie H., et al. The effects of clozapine and risperidone on spatial working memory in schizophrenia. Am J Psychiatry 162 (2005) 1013-1016
35. Medalia A., Gold J., and Merriam A. The effects of neuroleptics on neuropsychological test results of schizophrenics. Arch Clin Neuropsychol 3 (1988) 249-271
36. Meltzer H.Y., and McGurk S.R. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25 (1999) 233-255
37. Menon M.K., Lloyd R.L., and Fitten L.J. Antagonism of the hypothermic effect of clozapine in mice by centrally-active α2-adrenergic antagonists and α1-adrenergic agonists. Psychopharmacology 101 (1990) 67-72
38. Moore N.A., Leander J.D., Benvenga M.J., Gleason S.D., and Shannon H. Behavioral pharmacology of olanzapine: a novel antipsychotic drug. J Clin Psychiatry 58 (1997) 37-44
39. Ploeger G.E., Spruijt B.M., and Cools A.R. Effects of haloperidol on the acquisition of a spatial learning task. Physiol Behav 52 (1992) 979-983
40. Purdon S.E. Cognitive improvement in schizophrenia with novel antipsychotic medications. Schizophr Res 35 (1999) 51-60
41. Purdon S.E., Jones B.D., Stip E., Labelle A., Addington D., David S.R., et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Arch Gen Psychiatry 57 (2000) 249-258
42. Rasmussen T., Fink-Jensen A., Sauerberg P., Swedberg M.D.B., Thomsen C., Sheardown M.J., et al. The muscarinic receptor agonist BuTAC, a novel potential antipsychotic, does not impair learning and memory in mouse passive avoidance. Schizophr Res 49 (2001) 193-201
43. Rogers D.C., Robinson T.L., Quilter C.A., Hunter A.J., Routledge C., and Hagan J.J. Cognitive enhancement effects of the selective 5-HT6 antagonist SB-271046. Br J Pharmacol 127 (1999) [22 pp.]
44. Rosengarten H., and Quartermain D. The effect of chronic treatment with typical and atypical antipsychotics on working memory and jaw movements in three- and eighteen-month-old rats. Prog Neuropsychopharmacol Biol Psychiatry 26 (2002) 1047-1054
45. Roth B.L., Craigo S.C., Choudhary M.S., Uluer A., Monsma F.J., Shen Y., et al. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 268 (1994) 1403-1410
46. Sanfilipo M., Lafargue T., Rusinek H., Arena L., Loneragan C., Lautin A., et al. Cognitive performance in schizophrenia: relationship to regional brain volumes and psychiatric symptoms. Psychiatry Res 116 (2002) 1-23
47. Schotte A., Janssen P.F., Gommeren W., Luyten W.H., Van Gompel P., Lesage A.S., et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124 (1996) 57-73
48. Sharma T. Cognitive effects of conventional and atypical antipsychotics in schizophrenia. Br J Psychiatry 174 (1999) 44-51
49. Sharma T., and Mockler D. The cognitive efficacy of atypical antipsychotics in schizophrenia. J Clin Psychopharmacol 18 (1998) 12-19
50. Shirazi-Southall S., Rodriguez D.E., and Nomikos G.G. Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat. Neuropsychopharmacology 26 (2002) 583-594
51. Skarsfeldt T. Differential effect of antipsychotics on place navigation of rats in the Morris water maze. A comparative study between novel and reference antipsychotics. Psychopharmacology 124 (1996) 126-133
52. Spohn H.E., and Strauss M.E. Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. J Abnorm Psychol 98 (1989) 367-380
53. Stephenson C.M., and Pilowsky L.S. Psychological of olanzapine. A review. Br J Psychiatry Suppl 38 (1999) 52-58
54. Sumiyoshi T., Kurachi M., Kurokawa K., Yotsutsuji T., Uehara T., Itoh H., et al. Plasma homovanillic acid in the prodromal phase of schizophrenia. Biol Psychiatry 47 (2000) 428-433
55. Terry Jr. A.V., Hill W.D., Parikh V., Evans D.R., Waller J.L., and Mahadik S.P. Differential effects of chronic haloperidol and olanzapine exposure on brain cholinergic markers and spatial learning in rats. Psychopharmacology 164 (2002) 360-368
56. Tollefson G.D. Cognitive function in schizophrenic patients. J Clin Psychiaty 57 (1996) 31-39
57. Wolff M.C., and Leander J.D. Comparison of the effects of antipsychotics on a delayed radial maze task in the rat. Psychopharmacology 168 (2003) 410-416
58. Zhang W., and Bymaster F.P. The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT(2A) and muscarinic receptors. Psychopharmacology 141 (1999) 267-278